

K082176  
Pg 1 of 2

NOV 14 2008

**510(K) SUMMARY**

**LifeCell Corporation's LTM-BPS Surgical Mesh**

**Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared**

LifeCell Corporation  
One Millennium Way  
Branchburg, NJ 08869  
Phone: (908) 947-1115  
Facsimile: (908) 947-1095

Contact Person: Lorraine T. Montemurro, R.N., R.A.C.  
Date Prepared: October 23, 2008

**Name of Device and Name/Address of Sponsor**

LTM-BPS Surgical Mesh

LifeCell Corporation  
One Millennium Way  
Branchburg, NJ 08876

**Common or Usual Name**

Surgical Mesh

**Classification Name**

Surgical Mesh

**Predicate Devices**

LTM Surgical Mesh (K070560)

PelviSoft™ (K031332)

Permacol® (K013625)

**Intended Use / Indications for Use**

LTM-BPS Surgical Mesh is intended for use as a soft tissue patch to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue membranes which require the use of reinforcing or bridging material to obtain the desired surgical outcome. The implant is intended for reinforcement of soft tissues in plastic and reconstructive surgery.

LTM-BPS is intended for single patient, one time use only.

K082176

pg 202

### **Technological Characteristics**

The LTM-BPS is a surgical mesh that is derived from porcine skin. The LTM-BPS device consists of a terminally sterilized sheet of the processed porcine dermal matrix provided in prescribed geometric configurations and thicknesses, and packaged in double pouch configuration.

### **Performance Data**

The LTM-BPS has undergone extensive biocompatibility testing, animal testing, viral inactivation testing and biomechanical testing. The data indicate that the device is biocompatible and that the manufacturing process is capable of inactivating any viral components that may come with the starting material. The biomechanical data show that the LTM-BPS matrix possesses sufficient strength and suture retention for the intended use.

### **Substantial Equivalence**

LTM-BPS is substantially equivalent to legally marketed predicate devices, such as the LTM Surgical Mesh (K070560), PelviSoft™ (K031332) and Permacol® Implant (K013625) surgical mesh devices. LTM-BPS has the same intended uses and the same or similar indications, technological characteristics, and principles of operation as these predicate devices. Performance data demonstrate that LTM-BPS functions equivalently to the predicate devices. Thus, LTM-BPS is substantially equivalent.



## DEPARTMENT OF HEALTH &amp; HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

LifeCell Corporation  
c/o Ms. Lorraine T. Montemurro, R.N., RAC  
Senior Regulatory Affairs Manager  
One Millennium Way  
Branchburg, New Jersey 08876-3876

NOV 14 2008

Re: K082176  
Trade/Device Name: LTM-BPS Surgical Mesh  
Regulation Number: 21 CFR 878.3300  
Regulation Name: Surgical mesh  
Regulatory Class: II  
Product Code: FTM  
Dated: October 23, 2008  
Received: October 29, 2008

Dear Ms. Montemurro:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Ms. Lorraine T. Montemurro, R.N., RAC

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Mark N. Melkerson  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

K082176

**INDICATIONS FOR USE STATEMENT**

510(k) Number (if known): K082176

Device Name: LTM-BPS Surgical Mesh

Indications for Use:

LTM-BPS Surgical Mesh is intended for use as a soft tissue patch to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue membranes which require the use of reinforcing or bridging material to obtain the desired surgical outcome. The implant is intended for reinforcement of soft tissues in plastic and reconstructive surgery.

LTM-BPS is intended for single patient, one time use only.

Prescription Use X  
(Part 21 C.F.R. 801 Subpart D)

AND/OR

Over-The-Counter Use  
(21 C.F.R. 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF  
NEEDED)

\_\_\_\_\_  
Concurrence of CDRH, Office of Device Evaluation (ODE)

Mil F. Dohr for nxm  
(Division Sign-Off)  
**Division of General, Restorative,  
and Neurological Devices**

510(k) Number K082176